FDA Approves Autoinjector Device for Lerodalcibep-Liga, Updates Indication to Reflect MACE Risk Reduction

The FDA has approved an autoinjector device for lerodalcibep-liga (Lerochol; LIB Therapeutics), a third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alongside an updated indication statement reflecting the established link between low-density lipoprotein cholesterol (LDL-C) reduction and decreased risk of major adverse cardiovascular events (MACE). The autoinjector is expected to be available in the US by January 2027 at the same $199-per-month direct-to-patient cash price as the existing prefilled syringe. Lerodalcibep-liga was first approved in December 2025 as an adjunct to diet and exercise for lowering LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).^1,2

What Is Lerodalcibep-Liga?

Lerodalcibep-liga is a small protein-binding PCSK9 inhibitor built around an 11-kDa adnectin domain engineered for high-affinity binding to PCSK9, fused to human serum albumin to extend its plasma half-life. Unlike existing PCSK9 monoclonal antibodies, it is dosed as a single monthly subcutaneous injection and is stable at room temperature for up to 90 days. The newly approved autoinjector is a single-use, pressure-activated device designed to deliver a full dose in seconds; the prefilled syringe formulation remains available as an alternative.¹

Clinical Trials and Evidence

The original approval rested on the global phase 3 LIBerate Clinical Trial Program, which enrolled more than 2900 patients with cardiovascular disease (CVD) or without CVD but at high or very high risk, including those with heterozygous and homozygous FH. Patients received monthly dosing for up to 52 weeks in placebo-controlled trials, with over 2400 continuing into a 72-week open-label extension. Lerodalcibep-liga produced sustained LDL-C reductions of 60% or more in patients with or at high risk of cardiovascular disease and 59% or more in those with HeFH. Separately, extension data presented at the European Atherosclerosis Society meeting in Athens showed durable LDL-C lowering in patients with homozygous FH through 72 weeks, with reductions also observed in apoliprotein B and lipoprotein(a).^1-3

Contraindications, Warnings, and Precautions

The most common adverse reactions reported with lerodalcibep-liga in primary hyperlipidemia trials, occurring in at least 2% of patients and more frequently than placebo, were nasopharyngitis, local injection site reactions, and peripheral edema. In the HeFH population, injection site reactions were the most frequently reported adverse event, along with nasopharyngitis, diarrhea, nausea, and peripheral edema. Injection site reactions were also the most common reason for treatment discontinuation, occurring in 1% of lerodalcibep-liga-treated patients versus 0% on placebo. As a recombinant fusion protein, lerodalcibep-liga carries the potential for immunogenicity, a class-relevant consideration pharmacists should keep in mind when counseling patients on long-term use.¹

Conclusion

With the autoinjector slated for a January 2027 launch, pharmacists have a runway to prepare patient education materials ahead of the device's introduction. LIB Therapeutics has also submitted a Marketing Authorization Application to the European Medicines Agency, with a decision anticipated in the second half of 2026, and a Biologics License Application is pending in China.¹

REFERENCES

1. U.S. Food and Drug Administration approves an autoinjector version of LEROCHOL® (lerodalcibep-liga) and updated indication. News release. Businesswire. August 17, 2026. Accessed August 17, 2026. https://www.businesswire.com/news/home/20260817106971/en/U.S.-Food-and-Drug-Administration-Approves-an-Autoinjector-Version-of-LEROCHOL-lerodalcibep-liga-and-Updated-Indication

2. U.S. Food and Drug Administration approves LIB Therapeutics' LEROCHOL™ (lerodalcibep-liga) for adults with elevated LDL cholesterol. News release. LIB Therapeutics. December 15, 2025. Accessed August 17, 2026. https://libtherapeutics.com/news-and-events/us-food-and-drug-administration-approves-lib-therapeutics-lerochol-for-adults-with-elevated-ldl-cholesterol.html

3. LIB Therapeutics announces results from presentations on LEROCHOL® (lerodalcibep-liga) at the 2026 European Atherosclerosis Society meeting in Athens, May 24-26, 2026. News release. Businesswire. March 30, 2026. Accessed August 17, 2026. https://www.businesswire.com/news/home/20260330690384/en/LIB-Therapeutics-Announces-Results-from-Presentations-on-LEROCHOL-at-2026-American-College-of-Cardiology-meeting-in-New-Orleans-March-28-29-2026